Day: December 1, 2022

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting...

Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022

CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today...